{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T02:16:13Z","timestamp":1785204973852,"version":"3.55.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2017,4,21]],"date-time":"2017-04-21T00:00:00Z","timestamp":1492732800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2017,4,21]],"date-time":"2017-04-21T00:00:00Z","timestamp":1492732800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer Journal"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The absolute peripheral blood lymphocyte count at diagnosis is known to be a strong prognostic factor in patients with diffuse large B-cell lymphoma (DLBCL) treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP), but it remains unclear as to which peripheral blood lymphocyte population is reflective of DLBCL prognosis. In this cohort, 355 patients with DLBCL treated with R-CHOP from 2006 to 2013 were analyzed. The low absolute CD4+ T-cell count (ACD4C) at diagnosis negatively correlated with the overall response rate and the complete response rate significantly (<jats:italic>P<\/jats:italic>&lt;0.00001). An ACD4C&lt;343 \u00d7 10<jats:sup>6<\/jats:sup>\/l had a significant negative impact on the 5-year progression-free survival and the overall survival as compared with an ACD4C\u2a7e343 \u00d7 10<jats:sup>6<\/jats:sup>\/l (73.7% (95% confidence interval (CI)=66.7\u201379.5) versus 50.3% (95% CI=39.0\u201360.6), <jats:italic>P<\/jats:italic>&lt;0.00001 and 83.3% (95% CI=77.1\u201388.0) versus 59.0% (95% CI=47.9\u201368.5), <jats:italic>P<\/jats:italic>&lt;0.00000001, respectively). Multivariate analysis revealed that the ACD4C was an independent prognostic marker (hazard ratio=2.2 (95% CI=1.3\u20133.7), <jats:italic>P<\/jats:italic>&lt;0.01). In conclusion, a low ACD4C at diagnosis served as an independent poor prognostic marker in patients with DLBCL.<\/jats:p>","DOI":"10.1038\/bcj.2017.37","type":"journal-article","created":{"date-parts":[[2017,4,21]],"date-time":"2017-04-21T13:21:35Z","timestamp":1492780895000},"page":"e558-e558","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Low absolute peripheral blood CD4+ T-cell count predicts poor prognosis in R-CHOP-treated patients with diffuse large B-cell lymphoma"],"prefix":"10.1038","volume":"7","author":[{"given":"Y","family":"Kusano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Yokoyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y","family":"Terui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N","family":"Nishimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y","family":"Mishima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K","family":"Ueda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N","family":"Tsuyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y","family":"Hirofumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K","family":"Takeuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K","family":"Hatake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,4,21]]},"reference":[{"key":"BFbcj201737_CR1","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJM199309303291402","volume":"329","author":"MA Shipp","year":"1993","unstructured":"Shipp MA, Harrington DP, Anderson JR, Armitage JO, Bonadonna G, Brittinger G et al. A predictive model for aggressive NHL: the International non-Hodgkin\u2019s Lymphoma Prognostic Factors Project. N Engl J Med 1993; 329: 987\u2013994.","journal-title":"N Engl J Med"},{"key":"BFbcj201737_CR2","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.1182\/blood-2006-08-038257","volume":"109","author":"LH Sehn","year":"2007","unstructured":"Sehn LH, Berry B, Chhanabhai M, Fitzgerald C, Gill K, Hoskins P et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood 2007; 109: 1857\u20131861.","journal-title":"Blood"},{"key":"BFbcj201737_CR3","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1007\/s00262-001-0232-8","volume":"50","author":"T Mori","year":"2001","unstructured":"Mori T, Takada R, Watanabe R, Okamoto S, Ikeda Y . T-helper (Th)1\/Th2 imbalance in patients with previously untreated B-cell diffuse large cell lymphoma. Cancer Immunol Immunother 2001; 50: 566\u2013568.","journal-title":"Cancer Immunol Immunother"},{"key":"BFbcj201737_CR4","doi-asserted-by":"publisher","first-page":"2227","DOI":"10.1038\/sj.leu.2404780","volume":"21","author":"DH Kim","year":"2007","unstructured":"Kim DH, Baek JH, Chae YS, Kim YK, Kim HJ, Park YH et al. Absolute lymphocyte counts predicts response to chemotherapy and survival in diffuse large B-cell lymphoma. Leukemia 2007; 21: 2227\u20132230.","journal-title":"Leukemia"},{"key":"BFbcj201737_CR5","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1002\/ajh.21337","volume":"84","author":"LF Porrata","year":"2009","unstructured":"Porrata LF, Ristow K, Habermann TM, Witzig TE, Inwards DJ, Markovic SN . Absolute lymphocyte count at the time of first relapse predicts survival in patients with diffuse large B-cell lymphoma. Am J Hematol 2009; 84: 93\u201397.","journal-title":"Am J Hematol"},{"key":"BFbcj201737_CR6","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1038\/leu.2010.108","volume":"24","author":"LF Porrata","year":"2010","unstructured":"Porrata LF, Ristow K, Inwards DJ, Ansell SM, Micallef IN, Johnstonet PB et al. Lymphopenia assessed during routine follow-up after immunochemotherapy (R-CHOP) is a risk factor for predicting relapse in patients with diffuse large B-cell lymphoma. Leukemia 2010; 24: 1343\u20131349.","journal-title":"Leukemia"},{"key":"BFbcj201737_CR7","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1093\/annonc\/mdp505","volume":"21","author":"MK Song","year":"2010","unstructured":"Song MK, Chung JS, Seol YM, Kim SG, Shin HJ, Choi YJ et al. Influence of low absolute lymphocyte count of patients with nongerminal center type diffuse large B-cell lymphoma with R-CHOP therapy. Ann Oncol 2010; 21: 140\u2013144.","journal-title":"Ann Oncol"},{"key":"BFbcj201737_CR8","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/s12185-011-0993-6","volume":"95","author":"J Feng","year":"2012","unstructured":"Feng J, Wang Z, Guo X, Chen Y, Cheng Y, Tang Y . Prognostic significance of absolute lymphocyte count at diagnosis of diffuse large B-cell lymphoma: a meta-analysis. Int J Hematol 2012; 95: 143\u2013148.","journal-title":"Int J Hematol"},{"key":"BFbcj201737_CR9","doi-asserted-by":"publisher","first-page":"125","DOI":"10.3324\/haematol.2013.088161","volume":"99","author":"T Tadmor","year":"2014","unstructured":"Tadmor T, Bari A, Sacchi S, Marcheselli L, Liardo EV, Avivi I et al. Monocyte count at diagnosis is a prognostic parameter in diffuse large B-cell lymphoma: results from a large multicenter study involving 1191 patients in the pre- and post-rituximab era. Haematologica | 2014; 99: 125\u2013130.","journal-title":"Haematologica"},{"key":"BFbcj201737_CR10","first-page":"325","volume":"2","author":"T Tadmor","year":"2012","unstructured":"Tadmor T, Fell R, Polliack A, Attias D . Absolute monocytosis at diagnosis correlates with survival in diffuse large B-cell lymphoma\u2014possible link with monocytic myeloid-derived suppressor cells. Hematol Oncol 2012; 2: 325\u201331.","journal-title":"Hematol Oncol"},{"key":"BFbcj201737_CR11","doi-asserted-by":"publisher","first-page":"87","DOI":"10.3324\/haematol.2014.114934","volume":"100","author":"H Nitta","year":"2015","unstructured":"Nitta H, Terui Y, Yokoyama M, Mishima Y, Nishimura N, Ueda K et al. Absolute peripheral monocyte count at diagnosis predicts central nervous system relapse in diffuse large B-cell lymphoma. Haematologica 2015; 100: 87\u201390.","journal-title":"Haematologica"},{"key":"BFbcj201737_CR12","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.clml.2012.09.009","volume":"13","author":"N Batty","year":"2013","unstructured":"Batty N, Ghonimi E, Feng L, Fayad L, Younes A, Rodriguez MA et al. The absolute monocyte and lymphocyte prognostic index for patients with diffuse large B cell lymphoma who receive R-CHOP. Clin Lymphoma Myeloma Leuk 2013; 13: 15\u20138.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"BFbcj201737_CR13","doi-asserted-by":"publisher","first-page":"318","DOI":"10.3324\/haematol.2011.055038","volume":"97","author":"T Tadmor","year":"2012","unstructured":"Tadmor T, Benyamini N, Avivi I, Attias D, Polliack A . Absolute monocyte count is associated with adverse prognosis in diffuse large B-cell lymphoma: a validation study in a cohort of 219 patients from two centers. Haematologica 2012; 97: 318.","journal-title":"Haematologica"},{"key":"BFbcj201737_CR14","doi-asserted-by":"publisher","first-page":"4135","DOI":"10.1200\/JCO.2006.05.5897","volume":"24","author":"GW van Imhoff","year":"2006","unstructured":"van Imhoff GW, Boerma EJ, van der Holt B, Schuuring E, Verdonck LF, Kluin-Nelemans HC et al. Prognostic impact of germinal center-associated proteins and chromosomal breakpoints in poor-risk diffuse large B-cell lymphoma. J Clin Oncol 2006; 24: 4135\u20134142.","journal-title":"J Clin Oncol"},{"key":"BFbcj201737_CR15","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1126\/science.1076514","volume":"298","author":"ME Dudley","year":"2002","unstructured":"Dudley ME, Wunderlich JR, Robbins PF, Yang JC, Hwu P, Schwartzentruber DJ et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 2002; 298: 850\u2013854.","journal-title":"Science"},{"key":"BFbcj201737_CR16","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.1200\/JCO.2003.12.144","volume":"21","author":"AC Peterson","year":"2003","unstructured":"Peterson AC, Harlin H, Gajewski TE . Immunization with melan-A peptide-pulsed peripheral blood mononuclear cells plus recombinant human interleukin-12 induces clinical activity and T-cell response in advanced melanoma. J Clin Oncol 2003; 21: 2342\u20132348.","journal-title":"J Clin Oncol"},{"key":"BFbcj201737_CR17","doi-asserted-by":"publisher","first-page":"5346","DOI":"10.1182\/blood-2006-10-051318","volume":"109","author":"A Perez-Diez","year":"2007","unstructured":"Perez-Diez A, Joncker NT, Choi K, Chan WFN, Anderson CC, Lantz O et al. CD4 cells can be more efficient at tumor rejection than CD8 cells. Blood 2007; 109: 5346\u20135354.","journal-title":"Blood"},{"key":"BFbcj201737_CR18","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/j.immuni.2005.02.003","volume":"22","author":"A Corthay","year":"2005","unstructured":"Corthay A, Skovseth DK, Lundin KU, R\u00f8sj\u00f8 E, Omholt, Hofgaard PO et al. Primary antitumor immune response mediated by CD4+ T cells. Immunity 2005; 22: 381\u2013383.","journal-title":"Immunity"},{"key":"BFbcj201737_CR19","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.1038\/sj.leu.2403922","volume":"19","author":"T Lehrnbecher","year":"2005","unstructured":"Lehrnbecher T, Bernig T, Hanisch M, Koehl U, Behl M, Reinhardt D et al. Common genetic variants in the interleukin-6 and chitotriosidase genes are associated with the risk for serious infection in children undergoing therapy for acute myeloid leukemia. Leukemia 2005; 19: 1745\u20131750.","journal-title":"Leukemia"},{"key":"BFbcj201737_CR20","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1200\/JCO.2001.19.3.720","volume":"19","author":"SM Ansell","year":"2011","unstructured":"Ansell SM, Stenson M, Habermann TM, Jelinek DF, Witzig TE . CD4+ T-cell immune response to large B-cell non-Hodgkin\u2019s lymphoma predicts patient outcome. J Clin Oncol 2011; 19: 720\u2013726.","journal-title":"J Clin Oncol"},{"key":"BFbcj201737_CR21","doi-asserted-by":"publisher","first-page":"12589","DOI":"10.1007\/s13277-016-5124-9","volume":"37","author":"L He","year":"2016","unstructured":"He L, Liang JH, Wu JZ, Li Y, Qin SC, Miao Y et al. Low absolute CD4+ T cell counts in peripheral blood are associated with inferior survival in follicular lymphoma. Tumor Biol 2016; 37: 12589\u201312595.","journal-title":"Tumor Biol"},{"key":"BFbcj201737_CR22","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1111\/cas.13020","volume":"107","author":"XY Zhang","year":"2016","unstructured":"Zhang XY, Xu J, Zhu HY, Wang Y, Wang L, Fan L et al. Negative prognostic impact of low absolute CD4+ T cell counts in peripheral blood in mantle cell lymphoma. Cancer Sci 2016; 107: 1471\u20131476.","journal-title":"Cancer Sci"},{"key":"BFbcj201737_CR23","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.clml.2016.11.005","volume":"17","author":"J Judd","year":"2016","unstructured":"Judd J, Dulaimi E, Li T, Millenson MM, Borghaei H, Smith MR et al. Low level of blood CD4. T cells is an independent predictor of inferior progression-free survival in diffuse large B-cell lymphoma. Clin Lymphoma Myeloma Leuk 2016; 17: 83\u20138.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"BFbcj201737_CR24","unstructured":"Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H et al. WHO classification of tumours of haematopoietic and lymphoid tissues. World Health Organaization Classification of Tumours, IARC: Lyon, France, 2008."},{"key":"BFbcj201737_CR25","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1182\/blood-2003-05-1545","volume":"103","author":"CP Hans","year":"2004","unstructured":"Hans CP, Weisenburger DD, Greiner TC, Greiner TC, Gascoyne RD, Delabie J et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004; 103: 275\u2013282.","journal-title":"Blood"},{"key":"BFbcj201737_CR26","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","volume":"32","author":"BD Cheson","year":"2014","unstructured":"Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E et al. Recommendations for initial evaluation, staging, and response assessment of hodgkin and non-hodgkin lymphoma: the Lugano classification. J Clin Oncol 2014; 32: 3059\u20133067.","journal-title":"J Clin Oncol"},{"key":"BFbcj201737_CR27","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1093\/clinchem\/28.9.1905","volume":"28","author":"SH Ip","year":"1982","unstructured":"Ip SH, Rittershaus CW, Healey KW, Struzziero CC, Hoffman RA, Hansen PW . Rapid enumeration of T lymphocytes by a flow-cytometric immunofluorescence method. Clin Chem 1982; 28: 1905\u20131909.","journal-title":"Clin Chem"},{"key":"BFbcj201737_CR28","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1056\/NEJMoa011795","volume":"346","author":"B Coiffier","year":"2002","unstructured":"Coiffier B, Lepage E, Briere J, Herbrecht, Tilly H, Bouabdallah R et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 235\u2013242.","journal-title":"N Engl J Med"},{"key":"BFbcj201737_CR29","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","volume":"25","author":"BD Cheson","year":"2007","unstructured":"Cheson BD, Pfistner B, Juweid M, Gascoyne RD, Specht L, Horning SJ et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007; 25: 579\u2013586.","journal-title":"J Clin Oncol"},{"key":"BFbcj201737_CR30","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y . Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics. Bone Marrow Transplant 2013; 48: 452\u2013458.","journal-title":"Bone Marrow Transplant"},{"key":"BFbcj201737_CR31","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1093\/annonc\/mdn677","volume":"20","author":"D Ennishi","year":"2009","unstructured":"Ennishi D, Yokoyama M, Terui Y, Asai H, Sakajiri S, Mishima Y et al. Soluble interleukin-2 receptor retains prognostic value in patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP (RCHOP) therapy. Ann Oncol 2009; 20: 526\u2013533.","journal-title":"Ann Oncol"},{"key":"BFbcj201737_CR32","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1002\/ajh.23566","volume":"88","author":"A Rambaldi","year":"2013","unstructured":"Rambaldi A, Boschini C, Gritti G, Delaini F, Oldani E, Rossi A et al. The lymphocyte to monocyte ratio improves the IPI-risk definition of diffuse large B-cell lymphoma when rituximab is added to chemotherapy. Am J Hematol 2013; 88: 1062\u20131067.","journal-title":"Am J Hematol"},{"key":"BFbcj201737_CR33","doi-asserted-by":"publisher","first-page":"e41658","DOI":"10.1371\/journal.pone.0041658","volume":"7","author":"ZM Li","year":"2012","unstructured":"Li ZM, Huang JJ, Xia Y, Sun J, Huang Y, Wang Y et al. Blood lymphocyte-to-monocyte ratio identifies high-risk patients in diffuse large B-cell lymphoma treated with R-CHOP. PLoS One 2012; 7: e41658.","journal-title":"PLoS One"},{"key":"BFbcj201737_CR34","doi-asserted-by":"crossref","first-page":"5414","DOI":"10.18632\/oncotarget.14289","volume":"8","author":"J Wang","year":"2017","unstructured":"Wang J, Gao K, Lei W, Dong L, Xuan Q, Feng M et al. Lymphocyte-to-monocyte ratio is associated with prognosis of diffuse large B-cell lymphoma: correlation with CD163 positive M2 type tumor-associated macrophages, not PD-1 positive tumor-infiltrating lymphocytes. Oncotarget 2017; 8: 5414\u20135425.","journal-title":"Oncotarget"},{"key":"BFbcj201737_CR35","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1038\/leu.2011.112","volume":"25","author":"RA Wilcox","year":"2011","unstructured":"Wilcox RA, Ristow K, Habermann TM, Inwards DJ, Micallef INM, Johnston PB et al. The absolute monocyte and lymphocyte prognostic score predicts survival and identifies high-risk patients in diffuse large-B-cell lymphoma. Leukemia 2011; 25: 1502\u20131509.","journal-title":"Leukemia"},{"key":"BFbcj201737_CR36","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1086\/605292","volume":"49","author":"JA Aberg","year":"2009","unstructured":"Aberg JA, Kaplan JE, Libman H, Emmanuel P, Anderson JR, Stone VE et al. Primary care guidelines for the management of persons infected with human immunodeficiency virus: 2009 update by the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infec Dis 2009; 49: 651\u2013681.","journal-title":"Clin Infec Dis"},{"key":"BFbcj201737_CR37","unstructured":"Department for Health and Human services. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Available at: http:\/\/www.aidsinfo.nih.gov\/ (accessed 11 July 2016)."},{"key":"BFbcj201737_CR38","doi-asserted-by":"publisher","first-page":"1815","DOI":"10.1056\/NEJMoa0807252","volume":"360","author":"MM Kitahata","year":"2009","unstructured":"Kitahata MM, Gange SJ, Abraham AG, Merriman B, Saag MS, Justice AC et al. Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med 2009; 360: 1815\u20131826.","journal-title":"N Engl J Med"}],"updated-by":[{"DOI":"10.1038\/bcj.2017.43","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2017,5,12]],"date-time":"2017-05-12T00:00:00Z","timestamp":1494547200000}}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/bcj201737.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bcj201737","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/doifinder\/10.1038\/bcj.2017.37","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/www.nature.com\/articles\/bcj201737.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,22]],"date-time":"2022-12-22T17:25:54Z","timestamp":1671729954000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/bcj201737"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4,21]]},"references-count":38,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2017,4]]}},"alternative-id":["BFbcj201737"],"URL":"https:\/\/doi.org\/10.1038\/bcj.2017.37","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,4,21]]},"assertion":[{"value":"6 January 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2017","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 March 2017","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2017","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"YT has reported honoraria from Yanssen. MY has reported consultancy from Chugai. YM has reported consultancy from Chugai. NN has reported consultancy from Chugai. KH has reported consultancy from Meiji-Seika and Otsuka, honoraria from Kyowa Kirin and research Funding from Chugai and Kyowa Kirin. All other authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}